Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

P-glycoprotein is an efflux transporter encoded by the ABCB1 gene that actively pumps drugs out of cells, limiting their intracellular accumulation. It transports a wide range of medications including anticancer agents, cardiac drugs, and immunosuppressants. By expelling drugs across cell membranes, P-glycoprotein reduces drug bioavailability and can contribute to treatment resistance or require dose adjustments.

Genetic variations in the ABCB1 gene, such as the 3435C>T, 2677T>G, and 1236C>T polymorphisms, alter P-glycoprotein expression and function. These changes can increase drug concentrations in blood and tissues, leading to higher toxicity, chemotherapy resistance, or the need for dose adjustments in immunosuppressant therapy. Understanding these polymorphisms enables personalized medicine approaches.

Solute carrier transporters like OATP1B1 are influx transporters that facilitate drug uptake into cells, particularly in hepatic tissue. Unlike efflux transporters, they actively move drugs into cells rather than expelling them. This uptake mechanism is crucial for drug metabolism and clearance, especially for medications like statins that depend on hepatic processing.

Polymorphisms in the SLCO1B1 gene, particularly the c.521T>C variant, reduce transporter activity and hepatic uptake of statins like simvastatin. This results in higher plasma drug concentrations and increased risk of dose-dependent myopathy. Allelic variants such as SLCO1B1 *5, *15, and *17 occur at frequencies of 5-20% in many populations, supporting the need for genotype-guided dosing.

Drug transporter genetic variations significantly influence drug absorption, distribution, and elimination, creating interindividual differences in drug response. Recognizing these polymorphisms allows clinicians to tailor pharmacotherapy, reduce adverse effects, and improve clinical outcomes through individualized treatment strategies. This knowledge is essential for achieving safer and more effective patient care.

Efflux transporters like P-glycoprotein actively pump drugs out of cells, reducing intracellular drug concentration and bioavailability. Influx transporters like OATP1B1 facilitate drug movement into cells, enhancing uptake and metabolism. These opposing mechanisms regulate drug movement across cell membranes and significantly influence therapeutic drug levels and clinical outcomes.

Altered P-glycoprotein function due to genetic polymorphisms can result in increased drug toxicity, chemotherapy resistance, or altered drug distribution into sanctuary sites like the brain and testes. These changes may necessitate dose adjustments for medications like immunosuppressants or require alternative treatment strategies to achieve therapeutic goals and minimize adverse effects.